4 results
Primary purpose: study the feasibility of a new treatment option based on biofeedback in people with intellectual disabilities.Secondary purpose: explore effects of treatment for swallowing problems in people with intellectual disabilities.
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months